Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2023-08-25 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2023年半年度报告披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (417 characters) indicating that the company has approved and published its 2023 semi-annual report and summary on an official disclosure website. It does not contain the actual financial data or the report itself, but rather informs investors about the availability of the report. According to the 'MENU VS MEAL' rule, such a brief notice about report publication should be classified as a Report Publication Announcement (RPA), not as the Interim/Quarterly Report (IR) itself.
2023-08-25 Chinese
关于子公司向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about its subsidiary applying for a comprehensive credit facility from a bank. It includes details about the credit amount, purpose, and approvals from the board and supervisory committee. The document is relatively short (2097 characters) and focuses on financing activities rather than presenting financial statements or detailed financial performance. It does not contain a full financial report or earnings data but rather an update on financing arrangements. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-08-25 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled '云南沃森生物技术股份有限公司2023 年半年度报告全文' which translates to 'Yunnan Walvax Biotechnology Co., Ltd. 2023 Semi-Annual Report Full Text'. It contains detailed financial data, management discussion and analysis, company overview, business performance, product sales, production, and R&D activities for the first half of 2023. The document length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes financial metrics, risk disclosures, and operational details typical of an Interim / Quarterly Report. There is no indication that this is an Annual Report (10-K) or a simple announcement of report publication (RPA). Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese
2023年上半年募集资金存放与实际使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023 年上半年募集资金存放与实际使用情况专项报告" which translates to "Special Report on the Storage and Actual Use of Raised Funds for the First Half of 2023" by 云南沃森生物技术股份有限公司. The content details the amount of funds raised through share issuance, the use of these funds over multiple years, the management and storage of these funds in special accounts, changes in investment projects, and the use of idle raised funds to temporarily supplement working capital. It includes detailed tables of fund usage and changes in investment projects. The document is a specialized report focused on the status and use of capital raised by the company, specifically related to fundraising activities and the deployment of those funds. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is not a full annual or interim financial report, nor is it an announcement of a report publication. It is a substantive report on fundraising and capital usage. Therefore, the appropriate classification is CAP with high confidence.
2023-08-25 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 Half-Year Report Summary' (半年度报告摘要) for Yunnan Walvax Biotechnology Co., Ltd. It contains detailed financial data for the half-year period, including revenue, net profit, cash flow, earnings per share, and asset information. It also discusses shareholder information, share repurchase activities, and convertible bond issuance updates. The presence of comprehensive financial metrics and operational details for a half-year period indicates this is an Interim / Quarterly Report. The document length is over 5,000 characters and contains substantive financial data, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese
2023年半年度上市公司非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2023 by Yunnan Watson Biotechnology Co., Ltd. It includes specific financial data such as beginning balances, amounts occupied, interest, repayments, and ending balances for related parties and subsidiaries. The document is 2276 characters long, which is relatively short but contains substantive financial data and analysis for a half-year period. It is not an announcement or a brief summary but a financial report on related party transactions for the interim period. Therefore, it fits the definition of an Interim / Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2023
2023-08-25 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.